Article thumbnail

Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria

By Kris M Jamsen, Stephen B Duffull, Joel Tarning, Niklas Lindegardh, Nicholas J White and Julie A Simpson
Topics: Methodology
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3155838
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2011). A Research Agenda to Underpin Malaria Eradication. PLoS Med
  2. (2007). Abstr 1179.[http://www.page-meeting.org/?
  3. AJ: NONMEM Users Guides Icon Development Solutions, Ellicott City,
  4. (2000). Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs
  5. (1968). Cite this article as: Jamsen et al.: Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria.
  6. (2001). Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Meth Prog Biomed
  7. (2008). Duffull SB: Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.
  8. (2010). Duffull SB: Methods of robust design of nonlinear models with an application to pharmacokinetics.
  9. (2009). Duffull SB: Towards optimal design of antimalarial pharmacokinetic studies.
  10. (2002). Glucuronidation of Dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-Glucuronosyltransferases. Drug Metabolism and Disposition
  11. (2009). Kiechel JR: Population pharmacokinetics of artesunate and amodiaquine in African children.
  12. (2007). Kremsner PG: Pharmacokinetics of two paediatric artesunatemeoquine drug formulations in the treatment of uncomplicated falciparum malaria in Gabon.
  13. (2011). L: Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria.
  14. (2008). Lindegardh N: A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma.
  15. (2002). Maturation and growth of renal function: Dosing renally cleared drugs in children.
  16. (2004). NH: Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children.
  17. (2006). Nosten F: Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.
  18. (2009). NPJ: Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance.
  19. (2005). Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.
  20. (1997). Optimal design in random-effects regression models. Biometrika
  21. (2010). Organization: Guidelines for the treatment of malaria,
  22. (2011). Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC.
  23. (2009). Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria.
  24. (2006). POPT - Installation and user guide.
  25. (2008). White NJ: Antimalarial dosing regimens and drug resistance. Trends Parasitol
  26. (2009). White NJ: Artemisinin Resistance in Plasmodium falciparum Malaria.
  27. (2006). White NJ: Population pharmacokinetics of artesunate and dihydroartemisinin following intrarectal dosing of artesunate in malaria patients. PLoS Med
  28. (2006). White NJ: Sulfadoxinepyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther
  29. (2007). White NJ: World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
  30. World Wide Antimalarial Resistance Network.